浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
International comparative analysis of innovation recognition and price management of new drugs from the perspective of national healthcare security
- ZHONGGUO YAOFANG Vol. 35, Issue 15, Pages: 1801-1806(2024)
- 作者机构：
中国药科大学国际医药商学院，南京 211198
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2024.15.01
CLC： R951;F842.0;R197.1Published：15 August 2024，
Received：31 January 2024，
Revised：08 May 2024，
- 稿件说明：
扫 描 看 全 文
毛凯峰,虞杰,王琳宁等.医保视角下新药创新性认定与价格管理政策的国际对比分析 Δ[J].中国药房,2024,35(15):1801-1806.
MAO Kaifeng,YU Jie,WANG Linning,et al.International comparative analysis of innovation recognition and price management of new drugs from the perspective of national healthcare security[J].ZHONGGUO YAOFANG,2024,35(15):1801-1806.
毛凯峰,虞杰,王琳宁等.医保视角下新药创新性认定与价格管理政策的国际对比分析 Δ[J].中国药房,2024,35(15):1801-1806. DOI： 10.6039/j.issn.1001-0408.2024.15.01.
MAO Kaifeng,YU Jie,WANG Linning,et al.International comparative analysis of innovation recognition and price management of new drugs from the perspective of national healthcare security[J].ZHONGGUO YAOFANG,2024,35(15):1801-1806. DOI： 10.6039/j.issn.1001-0408.2024.15.01.
摘要
目的
2
为我国创新药价格体系的完善提供参考。
方法
2
基于我国创新药医保管理现状，对比分析国际典型国家或地区创新药认定与价格管理政策，提出完善我国创新药价格体系的建议。
结果与结论
2
中国台湾地区、日本、澳大利亚、德国以及英国对于药品创新性认定与分级、区分定价以及后续价格管理3个环节做法不同，但整体而言，都是主要依据药品的临床价值进行创新性认定和分级，依据分级进行差异化定价，并采用风险分担协议或主动价格调整进行价格管理。基于国内外政策对比，建议我国在创新药管理中进一步明晰创新的内涵与分级，应用多种定价方式促进创新分级管理，探索引入风险分担协议，并进一步构建主动药价调整机制，以完善我国创新药价格体系。
Abstract
OBJECTIVE
2
To provide reference for the improvement of the price system of innovative drugs in China.
METHODS
2
Based on the current situation of innovative drug healthcare management in China， innovation recognition and price management of innovative drugs in typical countries or regions were compared and analyzed， and the suggestions were put forward to improve the price system of innovative drugs in China.
RESULTS &CONCLUSIONS
2
Taiwan of China， Japan， Australia， Germany and the United Kingdom have different practices in recognition and grading of drug innovation， differentiated pricing and subsequent price management. However， the mainstream practice is to identify and grade drugs mostly based on clinical value， differentiate pricing based on the grading， and carry out risk-sharing agreement or active price adjustment to manage the price. Based on the comparative analysis， it is suggested that China should further clarify the connotation and classification of innovation in the management of innovative drugs， apply a variety of pricing methods to promote differentiated management of innovative drugs， explore the introduction of risk-sharing agreements， and further build an active drug price adjustment mechanism to improve the price system of innovative drugs in China.
关键词
创新药创新性认定差异化定价分级管理价格管理动态调整风险分担
Keywords
innovation recognitiondifferentiated pricinglevel-to-level administrationdrug price managementdynamic adjustmentrisk sharing
references
王雨阳，何敏媚.国外创新药纳入医保目录机制研究以及对我国的启示[J].中国药事，2023，37（7）：834-842.
WANG Y Y，HE M M. Research on the mechanism of foreign inclusion of innovative drugs in the list of medical insurance and its implications for China[J]. Chin Pharm Affair，2023，37（7）：834-842.
孔繁翠.创新药价值评估的国际经验比较及启示[J].中国卫生政策研究，2022，15（6）：17-23.
KONG F C. Comparison of international experience and enlightenment in the value assessment of innovative drugs[J]. Chin J Health Policy，2022，15（6）：17-23.
HOFMANN S，BRANNER J，MISRA A，et al. A review of current approaches to defining and valuing innovation in health technology assessment[J]. Value Health，2021，24（12）：1773-1783.
NICE. NICE health technology evaluations：the manual[EB/OL].（2022-01-31）[2024-01-13]. https：//www.nice.org.uk/process/pmg36/chapter/introduction-to-health-tech-nology-evaluationhttps://www.nice.org.uk/process/pmg36/chapter/introduction-to-health-tech-nology-evaluation.
厚生労働省.令和5年度薬価改定について[EB/OL]. （2023-02-15）[2024-01-13]. https：//www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411_00042.htmlhttps://www.mhlw.go.jp/stf/seisakunitsuite/bunya/0000188411_00042.html.
Ministry of Health，Labour and Welfare. 2023 NHI price revision[EB/OL].（2023-02-15）[2024-01-13]. https：//www.mhlw.go.jp/content/12404000/001169881.pdfhttps://www.mhlw.go.jp/content/12404000/001169881.pdf.
PBAC. Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee （PBAC）：version 5.0[EB/OL].（2016-09）[2024-01-13]. https：//pbac.pbs.gov.au/https://pbac.pbs.gov.au/.
全民健康保险药物给付项目及支付标准[EB/OL].（2023-08-23）[2024-01-13]. https：//law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0060035https://law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0060035.
National health insurance drug payment items and payment standards[EB/OL].（2023-08-23）[2024-01-13]. https：//law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0060035https://law.moj.gov.tw/LawClass/LawAll.aspx?PCode=L0060035.
蒋蓉，谢金平，邵蓉. 德国专利药早期效益评估与价格管理关键点探究[J]. 中国卫生经济，2021，40（5）：92-96.
JIANG R，XIE J P，SHAO R. Research on key points of early benefit assessment and price management concer- ning German patent medicines[J]. Chin Health Econ，2021，40（5）：92-96.
丁锦希，赵悦，丁志琛. 德国创新药物定价制度研究及其启示[J]. 价格理论与实践，2012（4）：44-45.
DING J X，ZHAO Y，DING Z C. Research on innovative drug pricing system in Germany and its enlightenment [J]. Price Theory Pract，2012（4）：44-45.
IQWiG. Drug approval and early benefit assessment in Germany[EB/OL]. [2024-01-13]. https：//www.iqwig.de/en/presse/in-the-focus/new-drugs-approval-benefit-assess- ment-coverage/1-drug-approval-and-early-benefit-assess- ment-in-germany/https://www.iqwig.de/en/presse/in-the-focus/new-drugs-approval-benefit-assess-ment-coverage/1-drug-approval-and-early-benefit-assess-ment-in-germany/.
STILLER I，VAN WITTELOOSTUIJN A，CAMBRÉ B. Do current radical innovation measures actually measure radical drug innovation?[J]. Scientometrics，2021，126（2）：1049-1078.
ZHANG Y C，WAGNER A K，GUAN X D. Newly approved cancer drugs in China：innovation and clinical benefit[J]. Nat Rev Clin Oncol，2023，20：135-136.
REJON-PARRILLA J C，ESPIN J，EPSTEIN D. How innovation can be defined，evaluated and rewarded in health technology assessment[J]. Health Econ Rev，2022，12（1）：1.
颜建周，李大双，任晓悦，等. 创新药医保准入差异化管理国际经验及启示[J]. 中国医疗保险，2023（1）：5-11.
YAN J Z，LI D S，REN X Y，et al. International expe- rience and enlightenment of innovative drug medical insurance access differentiated management[J]. China Health Insur，2023（1）：5-11.
常峰，崔鹏磊，张舰云，等. 全球视角下药品风险分担协议政策分析[J]. 卫生经济研究，2016（8）：39-44.
CHANG F，CUI P L，ZHANG J Y，et al. Policy analysis of drug risk sharing agreement from a global perspective[J]. Health Econ Res，2016（8）：39-44.
吕兰婷，傅金澜. 国家治理变革视角下的“药品医保生命周期”管理：来自日本的启示[J]. 中国卫生政策研究，2020，13（4）：73-80.
LYU L T，FU J L. Analysis of the “life cycle management of medical insurance” from the perspective of national governance reform：taking Japan as a reference[J]. Chin J Health Policy，2020，13（4）：73-80.
NHS England. NHS commercial framework for new medicines[EB/OL]. （2022-06-07）[2024-01-13]. https：//www.england.nhs.uk/publication/nhs-commercial-framework-for-new-medicines/https://www.england.nhs.uk/publication/nhs-commercial-framework-for-new-medicines/.
崔鹏磊，李世勇，常峰，等. 药品风险分担协议对中国大陆的启示：以澳大利亚、新西兰、中国台湾为例[J]. 中国卫生政策研究，2017，10（2）：21-26.
CUI P L，LI S Y，CHANG F，et al. The implementing experience of pharmaceutical risk-sharing agreements in Australia，New Zealand，Taiwan area and its implication for China’s mainland[J]. Chin J Health Policy，2017，10（2）：21-26.
杨姿锐，陶田甜，蒋蓉，等. 澳大利亚医保药品价格协议研究及对我国的启示[J]. 中国卫生经济，2020，39（6）：93-96.
YANG Z R，TAO T T，JIANG R，et al. Study on Australian deeds of agreement and its enlightenment to China[J]. Chin Health Econ，2020，39（6）：93-96.
DABBOUS M，CHACHOUA L，CABAN A，et al. Ma- naged entry agreements：policy analysis from the European perspective[J]. Value Health，2020，23（4）：425-433.
范长生，赵蒙蒙，谢洋，等. 关于医保谈判药品价值评估和支付标准形成的若干探讨[J]. 中国医疗保险，2020（11）：73-77.
FAN C S，ZHAO M M，XIE Y，et al. Discussion on the formation of drug value evaluation and payment standard in healthcare security negotiation[J]. China Health Insur，2020（11）：73-77.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8th Floor, Sihuan Building, No. 129 Daping Main Street, Yuzhong District, Chongqing, China Postal code：400042
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.